Sirolimus-Coated Balloon Versus Paclitaxel-Coated Balloon for the Treatment of Coronary In-Stent Restenosis

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 260 participants.

Also called NCT04240444

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 260 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04240444
Other papers using this trial's data
  • Sirolimus- vs Paclitaxel-Coated Balloon for the Treatment of Coronary In-Stent Restenosis: The SIBLINT-ISR Randomized Trial JACC. Cardiovascular interventions, 2025-04-28 DOI, PubMed 39985511

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04240444. Randomized; single masking; primary purpose treatment. Start 2020-10-10 (actual); primary completion 2022-07-26 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Sirolimus-Coated Balloon Versus Paclitaxel-Coated Balloon for the Treatment of Coronary In-Stent Restenosis
Acronym
SIBLINT ISR
Condition
In Stent Restenosis
Intervention (Device)
drug-coated balloon Catheter
Lead sponsor
B. Braun Medical International Trading Company Ltd. (class: industry)
Collaborator
CCRF Inc., Beijing, China (class: industry)

Record details

Record id
cardio:ct-nct04240444
Content hash
8e2c98b0fd96108a7f1d46101ffb16751e217ae2fd63147e58ce3fdf0914ccfe